• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home The Classics Hematology/Oncology Classics

Immune-related response criteria captures tumor response to therapy [Classics Series]

byDeepti Shroff Karhade
July 5, 2022
in Hematology/Oncology Classics, The Classics
Reading Time: 4 mins read
0
Share on FacebookShare on Twitter

This study summary is an excerpt from the book 2 Minute Medicine’s The Classics in Medicine: Summaries of the Landmark Trials

1. Immune-related response criteria should be used to capture the effects of immunotherapeutic agents as they more accurately capture the variable antitumor response seen after their use.

2. Ipilimumab monotherapy resulted in distinct response patterns that are not captured by the existing guidelines for tumor response described by Response Evaluation Criteria in Solid Tumors (RECIST) or other similar guidelines.

Original Date of Publication: November 2009

Study Rundown: The development of anticancer therapies spurred the development of novel methods for measuring therapy response. From early World Health Organization (WHO) criteria to more recent RECIST and RECIST 1.1 criteria, the development of a common language for the description of tumor response has been important for clinical and basic research. Importantly, these criteria have also established the guidelines for defining progressive disease (PD). However, the development of immunotherapeutic agents led to the clinical observation that the response criteria delineated by the WHO or RECIST guidelines did not seem to capture the response of these new, targeted therapies. Specifically, the original paradigm defined stable disease (SD) as a subset that had either not reached a definition for partial response (PR) or PD, and importantly, it was not viewed as an endpoint indicative of therapy response. In the immunotherapy trials however, stable disease has been used as a marker for improved clinical outcome. Another key difference observed in immunotherapy was that patients would often experience an increase in tumor burden before seeing an overall complete response, PR, or SD. Under the RECIST guidelines, a substantial increase in tumor burden would have represented PD, and led to the cessation of therapy, preventing researchers from demonstrating long-term therapeutic effects that may have occurred after this short-term increase in tumor burden. In 2004 and 2005, an expert panel of over 200 oncologists, immunotherapists, and industry experts convened to develop new guidelines that adequately accounted for these observed clinical differences in patients undergoing immunotherapy. This expert panel used the results obtained from a large clinical trial program of patients with advanced melanoma undergoing immunotherapy. They concluded that the appearance of antitumor activity may take longer for immune therapy than for cytotoxic therapy, and that the response to therapy may occur after PD. They also provided a definition for clinically insignificant PD and suggested that SD durability may represent true antitumor activity. Additionally, new criteria were established for the assessment of tumor response, named the immune-related response criteria (irRC), which allowed for new lesions to be included into tumor burden without necessarily signaling progressive disease.

Click to read the study in the Journal of Clinical Oncology

RELATED REPORTS

Nivolumab plus ipilimumab improves survival over lenvatinib or sorafenib in liver cancer

Nivolumab plus ipilimumab improves progression-free survival in metastatic colorectal cancer

Neoadjuvant ipilimumab plus nivolumab improves event-free survival in stage III melanoma

In-Depth [expert opinion]: An expert panel used the clinical observations obtained from the use of ipilimumab (an immunotherapy agent that directs human monoclonal antibodies to block CTLA-4 receptor) in patients with advanced melanoma. These clinical observations were obtained from phase II clinical trials that included a total of 487 patients from 3 centers and recorded the patterns of clinical response to immunotherapy. Patients were treated with induction therapy followed by maintenance therapy, and an independent committee used the original WHO criteria and irRC to evaluate tumor response. Patients were expected to experience an increase in tumor burden before a response was obtained, and continued immunotherapy if they had not developed clinical deterioration. About 30% of patients who were treated in the phase II trials had CR, PR, or SD at week 12. Patients with SD at week 12 also demonstrated a slow response (PR and CR) after week 12. Additionally, patients who had PD at week 12 also demonstrated a response to therapy or SD after week 12 with the continuation of immunotherapy. Four distinct patterns of tumor response were obtained: response in baseline lesions by week 12 with no new lesions, stable disease, response after an initial increase in total tumor burden, and a reduction of total tumor burden concurrent with the appearance of new lesions after week 12. WHO or RECIST guidelines had previously not described the latter two criteria. The irRC guidelines define tumor burden as the sum of diameters of index lesions and of new measurable lesions. Index lesions are defined as the two largest perpendicular diameters of all index lesions (with index lesions defined as up to five lesions per organ, 10 visceral lesions, and five cutaneous lesions). New lesions are limited to those that are greater than 5 mm, up to 5 new lesions per organ, 5 per cutaneous lesions, and 10 visceral lesions. For complete response (irRC), disappearance of a lesions must be confirmed by a consecutive evaluation no less than 4 weeks from the date of first documented complete disappearance. For partial response (irPR), a decrease in tumor burden must be greater than or equal to 50% relative to baseline and confirmed at least 4 weeks after documentation. For stable disease (irSD), response does not meet criteria for irCR or irPR, and there must be no evidence of disease progression. For disease progression (irPD), there must be an increase in tumor burden greater than or equal to 25% relative to the minimum recorded burden and must be confirmed by consecutive assessment at least 4 weeks from the date of first documentation. Patients could have irPR or irSD even in the presence of new lesions as long as they met the definitions of irPR or irSD. These new guidelines for measuring the response to immunotherapies allows for the incorporation of clinical criteria and flexible time points that were previously not captured by the guidelines set forth by RECIST 1.1.

Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, Lebbé C, et al. Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria. Clin Cancer Res. 2009 Dec 1;15(23):7412–20.

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: immune responseipilimumabrecistSystemic anticancer therapy (SACT)tumor burden
Previous Post

Risk of post-vitrectomy endophthalmitis may have increased during the COVID-19 pandemic

Next Post

Early exposure to allergenic foods may reduce incidence of long-term food allergy

RelatedReports

Prognostic indicators for transarterial chemoembolization in patients with hepatocellular carcinoma with extrahepatic spread identified
AI Roundup

Nivolumab plus ipilimumab improves survival over lenvatinib or sorafenib in liver cancer

June 12, 2025
Development of a risk index for colorectal cancer screening
Chronic Disease

Nivolumab plus ipilimumab improves progression-free survival in metastatic colorectal cancer

April 3, 2025
Increased risk of subsequent melanoma after first melanoma diagnosis
Dermatology

Neoadjuvant ipilimumab plus nivolumab improves event-free survival in stage III melanoma

December 12, 2024
#VisualAbstract: Neoadjuvant Nivolumab and Ipilimumab Improve Outcomes in Resectable Stage III Melanoma
Chronic Disease

#VisualAbstract: Neoadjuvant Nivolumab and Ipilimumab Improve Outcomes in Resectable Stage III Melanoma

June 18, 2024
Next Post
Peripregnancy nut consumption may decrease development of nut allergies

Early exposure to allergenic foods may reduce incidence of long-term food allergy

Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children

Remdesivir does not reduce mortality in ventilated patients with COVID-19

#VisualAbstract: Intravenous vitamin C increases mortality and organ dysfunction in sepsis patients

#VisualAbstract: Intravenous vitamin C increases mortality and organ dysfunction in sepsis patients

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Sodium-glucose cotransporter 2 inhibitors may decrease risk of serious liver events in patients with cirrhosis
  • #VisualAbstract: Lactated Ringer’s Solution Does Not Improve Outcomes Relative to Normal Saline
  • 2MM: AI Roundup – FDA’s AI Push, Trial Speedups with Real-World Data, Smart Surgical Monitors, and Regulatory Overhaul Begins [July 2nd, 2025]
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.